Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G).

Ticker(s): NVS

Who's the expert?

Institution: Columbia University

Academic nephrologist with expertise in glomerular diseases; Associate Professor of Medicine at Columbia University Medical Center.
Currently manages ~50 patients with Lupus Nephritis and ~50 patients with IgAN.
Clinical and research interests are focused on glomerular diseases; heavily involved in a variety of clinical and translational studies including the NIH-sponsored CureGN and NEPTUNE cohort studies.

Interview Goal

Discussing the effiacy/safety of iptacopan and how it compares to existing treatment options now that it has been FDA approved.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.